Brazikumab
drugOn this page
Also known as AMG-139MEDI-2070MEDI2070
Summary
Brazikumab (CHEMBL3833372) is a phase-3 clinical-stage antibody; indicated across 3 conditions including crohn disease and inflammatory bowel disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 3 conditions
- Clinical trials: 3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833372 |
| Name | Brazikumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: AMG-139, Brazikumab, MEDI-2070, MEDI2070, BRAZIKUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Crohn disease | 3 | MONDO:0005011 | EFO:0000384 |
| inflammatory bowel disease | 3 | MONDO:0005265 | EFO:0003767 |
| ulcerative colitis | 2 | MONDO:0005101 | EFO:0000729 |
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01714726 | PHASE2 | COMPLETED | Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn’s Disease. |
| NCT03616821 | PHASE2 | TERMINATED | Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| NCT05033431 | PHASE1 | COMPLETED | Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: Crohn disease, inflammatory bowel disease